We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
Cap. Flow
+$12.6M
Cap. Flow %
7.11%
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals
ELOX
+$5.07M
2
EDSA icon
Edesa Biotech
EDSA
+$3.85M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$3.63M
4
CABA icon
Cabaletta Bio
CABA
+$2.85M
5
MSLE
Satellos Bioscience
MSLE
+$2.69M

Top Sells

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$4.03M
2
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.46M
3
XOMA
Xoma
XOMA
+$2.18M
4
ABEO icon
Abeona Therapeutics
ABEO
+$1.04M
5
IKT icon
Inhibikase Therapeutics
IKT
+$1M

Sector Composition

Rank Sector Weight
1 Healthcare 74.11%
2 Miscellaneous 25.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
1
Verastem
VSTM
$723M
$12.8M 7.22%
3,349,627
+47,327
+1% +$229K
EOLS icon
2
Evolus
EOLS
$598M
$11M 6.23%
1,590,162
-168,929
-10% -$997K
TENX icon
3
Tenax Therapeutics
TENX
$66.6M
$9.6M 5.42%
660,000
-315,200
-32% -$4.03M
NKTR icon
4
Nektar Therapeutics
NKTR
$2.61B
$8.42M 4.75%
120,654
+35,654
+42% +$2.61M
ADMA icon
5
CALL
ADMA Biologics
ADMA
$2.15B
$7.95M 4.48%
650,000
-500,000
-43% -$4.56M
ADMA icon
6
ADMA Biologics
ADMA
$2.15B
$6.19M 3.49%
740,000
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$282M
$6.07M 3.43%
1,389,622
– –
INSM icon
8
CALL
Insmed
INSM
$27.7B
$5.6M 3.16%
+40,000
New +$4.84M
ELOX
9
Eloxx Pharmaceuticals
ELOX
$48.8M
$5.51M 3.11%
+397,160
New +$5.07M
RARE icon
10
CALL
Ultragenyx Pharmaceutical
RARE
$1.46B
$5.5M 3.1%
+200,000
New +$4.97M
KZIA
11
Kazia Therapeutics
KZIA
$189M
$4.86M 2.74%
345,179
– –
MDT icon
12
CALL
Medtronic
MDT
$119B
$4.38M 2.47%
+50,000
New +$4.03M
INDV icon
13
Indivior Pharmaceuticals
INDV
$4.11B
$4.1M 2.31%
+100,000
New +$3.63M
CRBP icon
14
Corbus Pharmaceuticals
CRBP
$222M
$3.99M 2.25%
425,000
+41,538
+11% +$393K
ABT icon
15
CALL
Abbott
ABT
$188B
$3.8M 2.14%
+40,000
New +$3.65M
MSLE
16
Satellos Bioscience
MSLE
$193M
$3.72M 2.1%
491,624
+391,624
+392% +$2.69M
ZVRA icon
17
Zevra Therapeutics
ZVRA
$745M
$3.71M 2.09%
258,701
-221,299
-46% -$2.46M
ABEO icon
18
Abeona Therapeutics
ABEO
$339M
$3.44M 1.94%
557,284
-189,303
-25% -$1.04M
BSX icon
19
CALL
Boston Scientific
BSX
$68B
$3.25M 1.83%
+50,000
New +$2.72M
EDSA icon
20
Edesa Biotech
EDSA
$45.9M
$3.19M 1.8%
456,439
+426,439
+1,421% +$3.85M
EOLS icon
21
CALL
Evolus
EOLS
$598M
$3.15M 1.78%
420,000
– –
BMRN icon
22
CALL
BioMarin Pharmaceuticals
BMRN
$12.9B
$3.13M 1.76%
+50,000
New +$2.74M
CABA icon
23
Cabaletta Bio
CABA
$590M
$2.85M 1.61%
917,100
+867,100
+1,734% +$2.85M
ANTX icon
24
AN2 Therapeutics
ANTX
$225M
$2.67M 1.51%
551,692
-162,153
-23% -$697K
XLO icon
25
Xilio Therapeutics
XLO
$59.4M
$2.17M 1.22%
225,994
+161,832
+252% +$1.35M
1
2 3 4 5

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.

  • Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
  • Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
  • Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
  • Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
  • Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
  • Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.